

ENZON PHARMACEUTICALS, INC.
Form 8-K
August 09, 2016

**UNITED STATES
SECURITIES AND
EXCHANGE
COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR
15(d) of The Securities
Exchange Act of 1934

Date of Report (Date of
earliest event reported):

August 9, 2016

**ENZON
PHARMACEUTICALS,
INC.**

(Exact name of registrant
as specified in its charter)

Delaware

0-12957

22-2372868

(State or other jurisdiction of (Commission File Number) (IRS Employer Identification No.)
incorporation)

20 Commerce Drive (Suite 135), Cranford, New Jersey 07016

(Address of principal executive offices)

(Zip Code)

(732) 980-4500

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On August 9, 2016, OTC Markets Group Inc. announced that the common stock of Enzon Pharmaceuticals, Inc. (the “Company”) has qualified to trade on the OTCQX® Best Market.

On August 9, 2016, the Company’s common stock began trading on OTCQX under the symbol “ENZN.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ENZON
PHARMACEUTICALS,
INC.**

(Registrant)

Date: August 9, 2016 By: /s/ Andrew Rackear
Name: Andrew Rackear

Title: Chief Executive
Officer and Secretary